PREOPERATIVE PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AND VELOCITY ARE STRONG AND INDEPENDENT PREDICTORS OF OUTCOMES FOLLOWING RADICAL PROSTATECTOMY
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 174 (6) , 2191-2196
- https://doi.org/10.1097/01.ju.0000181209.37013.99
Abstract
Prostate specific antigen (PSA) is a useful marker for predicting outcomes following treatment for prostate cancer but, given the evolving nature of prostate cancer, there is an ongoing need to refine its use. We assessed preoperative PSA doubling time (PSADT) and PSA velocity (PSAV) as predictors of outcome following radical retropubic prostatectomy (RRP). We identified 2,290 men who were treated with RRP for prostate cancer between 1990 and 1999 with multiple preoperative PSA measurements available. PSADT was calculated by log linear regression and PSAV was calculated by linear regression. These parameters were used in preoperative and postoperative multivariate models for the end points of biochemical and clinical progression, and cancer death. At a median followup of 7.1 years (range 0.1 to 14.5) biochemical progression, clinical progression and death from prostate cancer were observed in 583, 156 and 42 patients, respectively. The HR for death from prostate cancer was 6.22 (95% CI 3.33 to 11.61) in men with PSADT less than 18 months vs 18 or greater and 6.54 (95% CI 3.51 to 12.19) in men with PSAV greater than 3.4 ng/ml yearly vs 3.4 or less. On multivariate analysis adjusting for preoperative or postoperative variables PSADT and PSAV remained significant predictors of each outcome. When assessed jointly, PSAV was significant as a predictor of biochemical progression, while PSADT was a significant predictor of clinical progression and cancer death. This study confirms the usefulness of preoperative PSA kinetics for predicting post-RRP outcomes, which may be useful for stratifying patients, so that rational management decisions can be made with respect to observation, intervention and adjuvant treatment. While PSADT maybe biologically more accurate and stronger on multivariate analysis, PSAV is clinically easier to use and a good approximation in the short term.Keywords
This publication has 20 references indexed in Scilit:
- Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyNew England Journal of Medicine, 2004
- The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical ProstatectomyJournal of Urology, 2003
- Temporarily Deferred Therapy (watchful waiting) for Men Younger Than 70 Years and With Low-Risk Localized Prostate Cancer in the Prostate-Specific Antigen EraJournal of Clinical Oncology, 2003
- The dynamics of prostate specific antigen during watchful waiting of prostate carcinomaCancer, 2002
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001
- USE OF GLEASON SCORE, PROSTATE SPECIFIC ANTIGEN, SEMINAL VESICLE AND MARGIN STATUS TO PREDICT BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomyProstate Cancer and Prostatic Diseases, 2000
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updatePublished by American Medical Association (AMA) ,1997
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseJAMA, 1992